Davies, LixiLan-O Trial Investigators, Benefits of LixiLan, a titratable fixed-ratio combination of insulin Glargine plus Lixisenatide, versus insulin Glargine and Lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: The LixiLan-O randomized trial
Once youve reached a weight youre happy with, your provider may discuss staying on a lower or less frequent dose rather than stopping outright
Wegovy received UK marketing authorisation in 2023, and NICE guidance (TA875) supports its use within the NHS for adults with a BMI of at least 35 kg/m (or 30 kg/m with weight-related comorbidities), when provided through specialist weight management services, and for a maximum duration of 2 years
Key findings from body composition studies include: Visceral fat (the deep abdominal fat surrounding organs) decreases alongside subcutaneous fat Studies suggest that approximately 60-75% of weight loss comes from fat mass, with the remainder from lean tissue [17] [18] Waist circumferencea proxy measure for abdominal obesitytypically reduces by 6-10 cm on average in clinical trials [8] [9] Improvements in metabolic parameters often occur alongside reductions in visceral fat It is worth noting that individual responses vary considerably
most hotels offer discounts
